Thymosin Alpha-1 Benefits: Claims vs What Studies Show
Benefits people claim for Thymosin Alpha-1, set against what published studies measured, and where no study exists.
- Strongest evidence
- Human RCT
- Human / animal studies
- 11 / 0
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- approved abroad
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Immune system | Human RCT evidence, 4 of 4 | 5 / 0 | 28-day all-cause mortality; Safety and secondary outcomes; Infection rate and ICU stay | Evidence for immune system |
| Liver health | Human RCT evidence, 4 of 4 | 1 / 0 | Response rate; Low vs high dose; All-cause mortality | Evidence for liver health |
Strongest study per claim: Immune system, BMJ 2025, PMID 39814420; Liver health, Internal medicine 2003, PMID 14606705.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| 28-day all-cause mortality | 28-day mortality was 23.4% on thymosin alpha 1 and 24.1% on placebo (hazard ratio 0.99, P=0.93). | Human RCTn = 1106 | BMJ 2025, PMID 39814420 |
| Safety and secondary outcomes | No secondary or safety outcome differed significantly from placebo. | Human RCTn = 1106 | BMJ 2025, PMID 39814420 |
| Infection rate and ICU stay | Culture-positive rates and ICU stay were lower with thymosin alpha 1. | Human RCTn = 24 | Inflammation 2011, PMID 20549321 |
| Response and survival | Response was 57.1% vs 45.5%, not statistically different (P = 1.0). | Human RCTn = 25 | Hepatology international 2009, PMID 19669251 |
| Response rate | 37.5% (6 of 16) responded. | Human RCTn = 16 | Internal medicine 2003, PMID 14606705 |
| Low vs high dose | The low and high dose groups did not differ significantly. | Human RCTn = 16 | Internal medicine 2003, PMID 14606705 |
| Absorption and accumulation | Absorption was good with a Tmax of 1-2 hours across formulations. | Human RCTn = 9 | International journal of clinical pharmacology and therapeutics 1999, PMID 10027483 |
| Elimination half-life | No accumulation; elimination half-life under 3 hours. | Human RCTn = 9 | International journal of clinical pharmacology and therapeutics 1999, PMID 10027483 |
| Complete response at end of treatment | Complete response was 5 of 17 (29.4%) with T-alpha1 and 7 of 16 (43.8%) with interferon alfa, not significantly different. | Human RCTn = 33 | Hepatology 1996, PMID 8855175 |
| ALT normalisation | One thymosin alpha 1 patient and no placebo patient normalised ALT by the end of treatment. | Human RCTn = 19 | Liver 1996, PMID 8873009 |
| Non-recovery rate | After adjustment, thymosin alpha 1 use was associated with a higher non-recovery rate (OR 1.5); sicker patients were more likely to be treated. | Human observationaln = 2282 | Frontiers in immunology 2021, PMID 34408744 |
| CD4+ T cell recovery | CD4+ and CD8+ T cell increases did not differ between treated and untreated groups (p=0.851 and p=0.842). | Human observationaln = 275 | Frontiers in immunology 2021, PMID 34149679 |
| 28-day mortality in critical type | In the critical-type subgroup, thymosin alpha 1 was associated with lower 28-day mortality (HR 0.11, P=0.013). | Human observationaln = 334 | International immunopharmacology 2020, PMID 32795897 |
| HCV-RNA clearance and normal ALT at week 48 | Complete HCV-RNA clearance and normal ALT at week 48 in 45.5% of patients (combination with interferon). | Human uncontrolled trialn = 12 | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2001, PMID 11529376 |
| All-cause mortality | Pooled all-cause mortality was lower (RR 0.53) but certainty is very low. | Meta-analysisn = 1349 | The Cochrane database of systematic reviews 2026, PMID 42713852 |
| Histological improvement and quality of life | Little to no effect on quality of life or histology, with very low certainty. | Meta-analysisn = 1349 | The Cochrane database of systematic reviews 2026, PMID 42713852 |
| 28-day mortality (all RCTs) | Pooling all included RCTs, thymosin alpha 1 reduced 28-day mortality (OR 0.73, P = 0.003). | Meta-analysisn = 1927 | Frontiers in cellular and infection microbiology 2025, PMID 40969554 |
| High-quality and multicentre trials | High-quality (OR 0.82) and multicentre (OR 0.86) subgroups showed no significant mortality benefit. | Meta-analysisn = 1927 | Frontiers in cellular and infection microbiology 2025, PMID 40969554 |
| COVID-19 mortality | Mortality was lower (RR 0.59, p = 0.02) but ventilation need and hospital stay did not differ; heterogeneity was high. | Meta-analysis | Inflammopharmacology 2023, PMID 37845598 |
| COVID-19 mortality | Overall mortality did not differ (RR 1.03, p = 0.92); the authors do not support use in hospitalized adults. | Meta-analysisn = 5352 | International immunopharmacology 2023, PMID 36527881 |
Showing the first 20 of 23 rows, strongest sources first.
Claim: it boosts the immune system
A retrospective COVID-19 study found thymosin alpha 1 may have no benefit on restoring CD4+ and CD8+ T cell counts or on virus clearance.[9]
A sepsis review pooled 8 studies with 721 patients and found HLA-DR levels increased with thymosin alpha 1, one of the immune markers it measured.[27]
That review rated the evidence behind its conclusions as low, given small samples and weak reporting.[27]
Claim: it improves survival in sepsis
In the TESTS trial, 127 people (23.4%) on thymosin alpha 1 and 132 (24.1%) on placebo died within 28 days, a hazard ratio of 0.99.[1]
The TESTS authors found no clear evidence that it decreases 28 day all cause mortality in adults with sepsis.[1]
A pooled analysis of sepsis trials reported an odds ratio of 0.73 for 28-day mortality overall, but 0.82 in the high-quality trials and 0.86 in the multicentre ones, neither showing a benefit.[13]
Claim: it helps COVID-19
One pooled analysis of 8 studies found lower mortality with thymosin alpha-1 in moderate to critical COVID-19 (risk ratio 0.59), though it asks for randomised trials to verify it.[14]
Another pooled analysis found no statistically significant effect on mortality (risk ratio 1.03).[15]
A multicentre cohort study linked thymosin alpha 1 to a higher non-recovery rate after adjustment (odds ratio 1.5).[8]
Claim: it helps hepatitis and the liver
A Cochrane review in chronic hepatitis B said thymosin-alpha-1 may reduce all-cause mortality (risk ratio 0.53, 3 studies, 907 participants) on very low-certainty evidence.[12]
The same review concluded that the authors are not sure whether it reduces mortality or serious adverse events.[12]
Claim: bodybuilding and recovery
None of the 9 abstracts cached for this page studied athletes or measured muscle: they cover sepsis, COVID-19, chronic hepatitis B, and trial syntheses of those conditions.
Calculated from abstracts checked 39814420, 40969554, 27633969, 37845598, 36527881, 34408744, 32795897, 34149679, 42713852; athlete studies found 0. Formula: count of cached abstracts naming athletes or muscle outcomes
How much immune-system research exists
A PubMed search of thymosin alpha 1 with immune-system terms (2026-10-02) found 222 human-only papers and 101 under the animal filter; 42 carried a randomized-trial tag.
Calculated from pubmed query ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (immune[tiab] OR immunity[tiab] OR immunomodulat*[tiab] OR immunodefic*[tiab] OR immunostimul*[tiab]); date 2026-10-02; human only count 222; animal filter count 101; randomized filter count 42. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)
More on Thymosin Alpha-1
Common questions
Is Thymosin Alpha-1 proven to work?
The strongest study we summarise for Thymosin Alpha-1 is human rct evidence, among 18 studies. A trial result is not an approval; see the legal status.
What does thymosin alpha 1 do?
Thymalfasin is described as a 28-amino acid synthetic polypeptide, originally isolated from a bovine thymus extract.[28]
What is thymosin alpha 1 peptide used for in trials?
In the cached trials it was used as an immunomodulator, for example added to chemoembolization in unresectable hepatocellular carcinoma.[3]
More on Thymosin Alpha-1
Sources
- 1The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025PMID 39814420Accessed 2 Oct 2026
- 2Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.Inflammation · 2011PMID 20549321Accessed 2 Oct 2026
- 3A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.Hepatology international · 2009PMID 19669251Accessed 2 Oct 2026
- 4A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.Internal medicine (Tokyo, Japan) · 2003PMID 14606705Accessed 2 Oct 2026
- 5Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.International journal of clinical pharmacology and therapeutics · 1999PMID 10027483Accessed 2 Oct 2026
- 6A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.Hepatology (Baltimore, Md.) · 1996PMID 8855175Accessed 11 Oct 2026
- 7A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.Liver · 1996PMID 8873009Accessed 11 Oct 2026
- 8Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.Frontiers in immunology · 2021PMID 34408744Accessed 2 Oct 2026
- 9Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.Frontiers in immunology · 2021PMID 34149679Accessed 2 Oct 2026
- 10Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.International immunopharmacology · 2020PMID 32795897Accessed 2 Oct 2026
- 11The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.Journal of the Medical Association of Thailand = Chotmaihet thangphaet · 2001PMID 11529376Accessed 11 Oct 2026
- 12Thymosin-ɑ1 for people with chronic hepatitis B.The Cochrane database of systematic reviews · 2026PMID 42713852Accessed 2 Oct 2026
- 13Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in cellular and infection microbiology · 2025PMID 40969554Accessed 2 Oct 2026
- 14The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.Inflammopharmacology · 2023PMID 37845598Accessed 2 Oct 2026
- 15Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.International immunopharmacology · 2023PMID 36527881Accessed 2 Oct 2026
- 16PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) (956 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (randomized[tiab] OR "clinical trial"[pt] OR "meta-analysis"[pt]) (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (sepsis[tiab] OR septic[tiab]) (51 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (COVID-19[tiab] OR SARS-CoV-2[tiab]) (44 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (hepatitis[tiab]) (131 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND ("meta-analysis"[pt] OR "systematic review"[pt]) (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 23PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (allerg*[tiab] OR asthma[tiab] OR rhinitis[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 24PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (143 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 25PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (randomized[tiab] OR "clinical trial"[pt] OR "phase II"[tiab] OR "phase I"[tiab]) AND ("adverse events"[tiab] OR "adverse effects"[tiab] OR toxicity[tiab] OR "injection site"[tiab] OR tolerated[tiab]) (37 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 26PubMed search: ("thymosin alpha 1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab]) AND ("injection site"[tiab] OR "local discomfort"[tiab] OR "side effects"[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 27The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.BMC infectious diseases · 2016PMID 27633969Accessed 2 Oct 2026
- 28Thymalfasin for the treatment of chronic hepatitis B.Expert review of anti-infective therapy · 2004PMID 15482167Accessed 2 Oct 2026
Found an error? Report a correction.